MedPath

The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

Phase 2
Completed
Conditions
Angioplasty, Transluminal, Percutaneous Coronary
Registration Number
NCT00133731
Lead Sponsor
Sanofi
Brief Summary

The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
947
Inclusion Criteria
  • 18 years of age or older
  • Due to undergo non-urgent percutaneous coronary intervention (PCI)
  • Planned treatment with aspirin and clopidogrel
Exclusion Criteria
  • Recent acute coronary syndrome
  • Patients at risk for, or with prior recent, bleeding
  • Patients have received recent prior treatment with an anticoagulant
  • Creatinine clearance > 30 ml/min

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Death, myocardial infarction, and urgent and non-urgent target vessel revascularization
Secondary Outcome Measures
NameTimeMethod
Bleeding events

Trial Locations

Locations (89)

Los Angeles Cardiology Associates

🇺🇸

Los Angeles, California, United States

Anil V. Shah, MD

🇺🇸

Santa Ana, California, United States

George Washington University Medical Faculty Associates

🇺🇸

Washington, District of Columbia, United States

Florida Cardiovascular Research

🇺🇸

Atlantis, Florida, United States

Ocala Research Institute, Inc

🇺🇸

Ocala, Florida, United States

Central Florida Cardiology Group, PA

🇺🇸

Orlando, Florida, United States

Cardiology Associates, PA

🇺🇸

Panama City, Florida, United States

Heart Specialists of Sarasota

🇺🇸

Sarasota, Florida, United States

Cardiac Disease Specialists

🇺🇸

Atlanta, Georgia, United States

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Scroll for more (79 remaining)
Los Angeles Cardiology Associates
🇺🇸Los Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.